恶性胸膜间皮瘤免疫治疗的新视野
New horizons from immunotherapy in malignant pleural mesothelioma.
作者信息
Calabrò Luana, Rossi Giulia, Maio Michele
机构信息
Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
出版信息
J Thorac Dis. 2018 Jan;10(Suppl 2):S322-S332. doi: 10.21037/jtd.2017.12.88.
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive disease with a severe prognosis. Medical treatment for MPM unresectable patients is still unsatisfactory; therefore novel therapeutic approaches are urgently needed. Immunotherapy represents a promising treatment for MPM patients. Here, we'll discuss the most promising immunotherapeutic treatments currently under active investigation for this still dreadful disease.
摘要
恶性胸膜间皮瘤（MPM）是一种侵袭性疾病，预后严重。对于无法切除的MPM患者，药物治疗仍不尽人意；因此，迫切需要新的治疗方法。免疫疗法是MPM患者一种有前景的治疗方式。在此，我们将讨论目前针对这种仍然可怕的疾病正在积极研究的最有前景的免疫治疗方法。
相似文献
1
New horizons from immunotherapy in malignant pleural mesothelioma.恶性胸膜间皮瘤免疫治疗的新视野
J Thorac Dis. 2018 Jan;10(Suppl 2):S322-S332. doi: 10.21037/jtd.2017.12.88.
2
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的免疫治疗方法
Cancers (Basel). 2021 Jun 4;13(11):2793. doi: 10.3390/cancers13112793.
3
[Anti-tumor immunotherapy in malignant pleural mesothelioma].[恶性胸膜间皮瘤的抗肿瘤免疫治疗]
Rev Mal Respir. 2018 Apr;35(4):465-476. doi: 10.1016/j.rmr.2017.07.025. Epub 2018 Feb 4.
4
Emerging therapies in malignant pleural mesothelioma.恶性胸膜间皮瘤的新兴疗法。
Crit Rev Oncol Hematol. 2019 Dec;144:102815. doi: 10.1016/j.critrevonc.2019.102815. Epub 2019 Oct 5.
5
Current status and progress in immunotherapy for malignant pleural mesothelioma.恶性胸膜间皮瘤免疫治疗的现状与进展
Chronic Dis Transl Med. 2022 Mar 31;8(2):91-99. doi: 10.1002/cdt3.18. eCollection 2022 Jun.
6
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.间皮瘤的免疫检查点阻断治疗：临床和影像学挑战。
Cancer Immunol Immunother. 2018 Aug;67(8):1317-1324. doi: 10.1007/s00262-018-2191-3. Epub 2018 Jun 26.
7
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).治疗不可切除恶性胸膜间皮瘤的新方法：聚焦免疫治疗和靶向治疗（综述）
Mol Clin Oncol. 2022 Apr;16(4):89. doi: 10.3892/mco.2022.2522. Epub 2022 Feb 22.
8
New therapeutic strategies for malignant pleural mesothelioma.恶性胸膜间皮瘤的新治疗策略
Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16.
9
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.免疫检查点抑制剂在恶性胸膜间皮瘤中不断演变的作用
J Clin Med. 2023 Feb 22;12(5):1757. doi: 10.3390/jcm12051757.
10
What's the place of immunotherapy in malignant mesothelioma treatments?免疫疗法在恶性间皮瘤治疗中的地位如何？
Cell Adh Migr. 2010 Jan-Mar;4(1):153-61. doi: 10.4161/cam.4.1.11361. Epub 2010 Jan 30.
引用本文的文献
1
Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis.18F-FDG PET/CT的最大标准摄取值、代谢肿瘤体积和总病变糖酵解对恶性胸膜间皮瘤患者的预后价值：一项系统评价和荟萃分析
Cancer Cell Int. 2022 Feb 3;22(1):60. doi: 10.1186/s12935-022-02482-5.
2
A Review of Pharmacologic Management in the Treatment of Mesothelioma.《间皮瘤治疗中的药物治疗管理综述》。
Curr Treat Options Oncol. 2021 Jan 12;22(2):14. doi: 10.1007/s11864-020-00807-y.
3
Is there a role for immunotherapy in malignant pleural mesothelioma?免疫疗法在恶性胸膜间皮瘤中的作用如何？
Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x.
本文引用的文献
1
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.人用首仿，多中心，I 期剂量递增和扩展研究抗间皮素抗体药物偶联物 Anetumab Ravtansine 在晚期或转移性实体瘤中的应用。
J Clin Oncol. 2020 Jun 1;38(16):1824-1835. doi: 10.1200/JCO.19.02085. Epub 2020 Mar 26.
2
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.特美替尼二线或三线治疗复发性恶性间皮瘤（DETERMINE）：一项多中心、国际、随机、双盲、安慰剂对照的 2b 期试验。
Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.
3
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.帕博利珠单抗治疗恶性胸膜间皮瘤患者的临床安全性和疗效（KEYNOTE-028）：一项非随机、开放标签、Ib 期试验的初步结果。
Lancet Oncol. 2017 May;18(5):623-630. doi: 10.1016/S1470-2045(17)30169-9. Epub 2017 Mar 11.
4
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.间皮瘤中的免疫微环境、全基因组拷贝数异常与生存
J Thorac Oncol. 2017 May;12(5):850-859. doi: 10.1016/j.jtho.2017.02.013. Epub 2017 Feb 28.
5
PD-1 and PD-L1 antibodies in cancer: current status and future directions.癌症中的PD-1和PD-L1抗体：现状与未来方向。
Cancer Immunol Immunother. 2017 May;66(5):551-564. doi: 10.1007/s00262-017-1954-6. Epub 2017 Feb 17.
6
Advances in Cancer Immunotherapy in Solid Tumors.实体瘤癌症免疫治疗的进展
Cancers (Basel). 2016 Nov 24;8(12):106. doi: 10.3390/cancers8120106.
7
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?间皮素免疫疗法治疗癌症：准备好进入黄金时代了吗？
J Clin Oncol. 2016 Dec;34(34):4171-4179. doi: 10.1200/JCO.2016.68.3672. Epub 2016 Oct 31.
8
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.PD-L1 阳性恶性胸膜间皮瘤中的细胞毒性 T 细胞受到独特免疫抑制因子的抑制。
Cancer Immunol Res. 2016 Dec;4(12):1038-1048. doi: 10.1158/2326-6066.CIR-16-0171. Epub 2016 Nov 14.
9
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.靶向间皮素的新型抗体疗法治疗实体瘤
Clin Cancer Drugs. 2016 Oct;3(2):76-86. doi: 10.2174/2212697X03666160218215744.
10
Immunotherapy for malignant mesothelioma: reality check.恶性间皮瘤的免疫疗法：现状审视
Expert Rev Anticancer Ther. 2016 Nov;16(11):1167-1176. doi: 10.1080/14737140.2016.1241149. Epub 2016 Oct 6.
Zotero 插件